# Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

> **NCT01091142** · PHASE1 · COMPLETED · sponsor: **Neuraltus Pharmaceuticals, Inc.** · enrollment: 56 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** NP001
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01091142
- **Lead sponsor:** Neuraltus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-09
- **Final completion:** —
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2010-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01091142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01091142, "Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01091142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*